EGFR and lung cancer: Recently, several third-generation, irreversible, selective EGFR inhibitors such as AZD9291 and CO1686 have shown promise in pre-clinical studies and provided hope for patients with advanced lung cancers that have become resistant to gefitinib or erlotinib.